Diabetic Retinopathy Market Size Worth $15.23 Billion By 2032 | CAGR: 6.30%

Diabetic Retinopathy Market Size Worth $15.23 Billion By 2032 | CAGR: 6.30%

The global diabetic retinopathy market size is expected to reach USD 15.23 billion by 2032, according to a new study by Polaris Market Research. The report “Diabetic Retinopathy Market Share, Size, Trends, Industry Analysis Report, By Type (Proliferative DR, Non-proliferative DR); By Management (Intraocular Steroid Injection, Laser Surgery, Vitrectomy); By Region, And Segment Forecasts, 2024 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The incidence of diabetes has been witnessing a significant surge, with a substantial impact on global health. According to the International Diabetes Federation, the number of individuals affected by diabetes was approximately 537 million in 2021. This figure is projected to increase to 643 million by 2030 and a staggering 783 million by 2045. Diabetes is recognized as one of the leading causes of blindness worldwide.

Blindness in individuals with diabetes is often attributed to the damage caused by leaking or ruptured blood vessels in the retina. The severity of vision loss can vary, ranging from permanent impairment to temporary disruptions depending on the stage of the disease. Research indicates that the number of cases of diabetic retinopathy, a specific form of vision impairment associated with diabetes, was estimated to be around 103.12 million in 2020. It is anticipated that the number of cases will escalate to approximately 160.5 million by 2045.

Do you have any questions? Would you like to request a sample or make an inquiry before purchasing this report? Simply click the link below: https://www.polarismarketresearch.com/industry-analysis/diabetic-retinopathy-market/request-for-sample

The aging population presents unique challenges in terms of healthcare needs, including a higher prevalence of chronic diseases like diabetes. With advancements in medical care and improved life expectancy, the number of individuals aged 65 years and over is projected to escalate substantially. For instance, the "Aging in the United States" report by the Population Reference Bureau indicates that the population of individuals aged 65 years and above in the U.S. is estimated to grow from approximately 46 million in 2016 to over 98 million by the year 2060.

This demographic shift underscores the importance of addressing health issues associated with aging, including diabetic retinopathy. Healthcare providers and manufacturers in the market must be prepared to meet the growing demands of this expanding population and provide effective solutions to manage diabetic retinopathy and preserve vision in older adults.

The COVID-19 pandemic had a substantial impact on healthcare systems worldwide, including the diagnosis and treatment of diabetic retinopathy. Due to the constraints and restrictions imposed during the pandemic, early detection and treatment guidelines for diabetic retinopathy were significantly affected. Intravitreal injections, which are a common treatment modality for diabetic retinopathy, experienced a significant decrease in usage globally during the pandemic compared to 2019. Reduction percentages varied but ranged from approximately 30% to over 100%.

Diabetic Retinopathy Market Report Highlights

  • Non-proliferative diabetic retinopathy segment accounted for highest global market share in 2022, due to rise in number of cases of diabetes
  • Anti-VEGF segment accounted largest share, due its high efficacy and better treatment algorithm
  • Asia Pacific region grown at the fastest rate, owing huge un-tapped population and better patient awareness
  • The global key market players include Bayer, Allergan, Novartis, Oxurion, Sirnaomics, Genentech, Alimera Sciences, Ampio Pharmaceuticals, BCN Peptides, and Kowa Company.

Polaris Market Research has segmented the diabetic retinopathy market report based on type, management, and region:

Diabetic Retinopathy, Type Outlook (Revenue - USD Billion, 2019 - 2032)

  • Proliferative Diabetic Retinopathy
  • Non-proliferative diabetic retinopathy

Diabetic Retinopathy, Management Outlook (Revenue - USD Billion, 2019 - 2032)

  • Anti-VEGF
  • Intraocular Steroid Injection
  • Laser Surgery
  • Vitrectomy

Diabetic Retinopathy, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Diabetic Retinopathy Market Report Scope

Report Attributes


Market size value in 2024

USD 9.31 billion

Revenue forecast in 2032

USD 15.23 billion


6.30% from 2024 – 2032

Base year


Historical data

2019 – 2022

Forecast period

2024 – 2032

Quantitative units

Revenue in USD billion and CAGR from 2024 to 2032

Segments covered

By Type, By Management, By Region

Regional scope

North America, Europe, Asia Pacific, Latin America; Middle East & Africa

Key companies

Bayer, Allergan, Novartis, Oxurion, Sirnaomics, Genentech, Alimera Sciences, Ampio Pharmaceuticals, BCN Peptides, and Kowa Company

For Specific Research Requirements

Request for Customized Report